TY - JOUR AU - Pankiv, V.I. PY - 2019/10/30 Y2 - 2024/03/28 TI - Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus JF - INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) JA - Mìžnarodnij endokrinologìčnij žurnal VL - 15 IS - 6 SE - Literature Review DO - 10.22141/2224-0721.15.6.2019.185411 UR - https://iej.zaslavsky.com.ua/index.php/journal/article/view/212 SP - 482-487 AB - Incretin hormones are important for the normal functioning of pancreatic islet cells and glucose homeostasis. In type 2 diabetes mellitus, there is a violation of the sensiti­vity of pancreatic α- and β-cells, which leads to progressive insufficient insulin secretion, insulin resistance due to excessive production of glucagon during periods of postprandial hyperglycemia. In addition, type 2 diabetes mellitus is associated with an increase in lipotoxicity directly related to insulin resistance. The literature review provides data on the safety and efficacy of vildagliptin in patients with type 2 diabetes mellitus, as well as on the pancreatic effects of incretin-targeted therapy. It is clinically confirmed that vildagliptin effectively reduces the level of glycated hemoglobin, has a minimal risk of hypoglycemia and is able to maintain a normal body weight. In addition, vildagliptin inhibits postprandial triglyceride production and decreases fas­ting lipolysis, possibly affecting the inhibition of lipid absorption and triglyceride stores in non-adipose tissue cells. ER -